Journal of diabetes and its complications最新文献

{"title":"The prevalence and correlates of advanced fibrosis in patients with and without diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A cross-sectional study.","authors":"Emir Muzurović, Goran Topić, Nevena Todorović, Manfredi Rizzo, Ksenija Zečević","doi":"10.1016/j.jdiacomp.2025.109147","DOIUrl":"10.1016/j.jdiacomp.2025.109147","url":null,"abstract":"<p><strong>Background: </strong>The severity of liver fibrosis serves as a crucial prognostic indicator, reflecting liver-related and cardiovascular-related outcomes, as well as mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Type 2 diabetes mellitus (T2DM) is a major risk factor for developing metabolic dysfunction-associated steatohepatitis (MASH), and in patients with both T2DM and MASH, identifying those with advanced fibrosis is critical.</p><p><strong>Methods: </strong>This cross-sectional study included 162 MASLD patients (47 with T2DM, 38 with prediabetes and 77 individuals without diabetes). The aim of this study was to determine the prevalence of advanced fibrosis in MASLD patients with and without DM and prediabetes, using a 2-step approach with fibrosis-4 index followed by liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE), and to evaluate the predictive cardiometabolic risk factors for the development of advanced fibrosis in these patients.</p><p><strong>Results: </strong>Among patients with prediabetes and T2DM, 12.9 % were identified with F3 stage fibrosis, 6.5 % had F4 stage, totaling 19.4 % with advanced fibrosis or cirrhosis, assessed by VCTE. In contrast, among individuals without diabetes, 1.78 % was found to have F3 stage fibrosis, while 7.14 % had F4. In patients with T2DM or prediabetes, body mass index (BMI) was a significant predictor of advanced fibrosis (p = 0.02), with each unit increase in BMI linked to a 1.3-fold higher risk of advanced fibrosis and cirrhosis, and higher high-density lipoprotein cholesterol (HDL-C) levels were associated with lower odds of having F3 or F4 stage fibrosis (p = 0.04). In MASLD patients without diabetes, triglycerides (TGs) showed a significant positive correlation with liver stiffness (p = 0.04), male sex was significantly associated with a higher susceptibility to increased liver stiffness (p = 0.04), and males had 0.91 times the odds of developing advanced fibrosis and cirrhosis (p = 0.02). No significant correlations were observed between liver stiffness and age, sex, aspartate aminotransferase (AST), alanine aminotransferase (ALT), glucose levels, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), or TGs in patients with T2DM or prediabetes. In MASLD patients without diabetes, no significant correlations were found between liver stiffness and factors such as age, BMI, AST, ALT, TC, LDL-C, HDL-C, or glucose levels.</p><p><strong>Conclusion: </strong>In conclusion, the prevalence of advanced fibrosis or cirrhosis in patients with both, MASLD and T2DM, is very high. In MASLD patients with T2DM or prediabetes, higher BMI and lower levels of HDL-C are significant predictors of advanced fibrosis or cirrhosis.</p>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"109147"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparative analysis of cost-utility: Chiglitazar vs. sitagliptin in patients with type 2 diabetes in China","authors":"Zeyu Xie ,&nbsp;Zhuoru Liang ,&nbsp;Guimei Zheng ,&nbsp;Weiling Cao","doi":"10.1016/j.jdiacomp.2025.109174","DOIUrl":"10.1016/j.jdiacomp.2025.109174","url":null,"abstract":"<div><h3>Background</h3><div>As a structurally unique peroxisome proliferator-activated receptor pan-agonist, chiglitazar has showed dual therapeutic benefits for glycemic control and lipid management in type 2 diabetes mellitus (T2DM). Despite these clinical advantages, comprehensive pharmacoeconomic evaluations comparing chiglitazar with conventional therapies like sitagliptin remain unavailable for China's healthcare system.</div></div><div><h3>Objective</h3><div>This study aimed to conduct a comparative cost-utility analysis of chiglitazar versus sitagliptin for T2DM treatment in China, evaluating long-term clinical and economic outcomes from a healthcare system perspective.</div></div><div><h3>Methods</h3><div>Data on patient demographics and post-treatment effects were collected from a double-blind, phase 3, randomized controlled trial conducted in China. The United Kingdom Prospective Diabetes Study Outcomes Model 2.1 was employed to evaluate the long-term effectiveness and associated costs. Uncertainties were addressed using one-way and probabilistic sensitivity analyses. Additionally, the binary search method was utilized to estimate an optimal annual cost for sitagliptin in scenario analyses.</div></div><div><h3>Results</h3><div>After a 40-year simulation, the life expectancy results were comparable among treatments: 14.93 years for chiglitazar 32 mg, 14.94 years for chiglitazar 48 mg, and 14.93 years for sitagliptin 100 mg. The corresponding quality-adjusted life years (QALYs) reached 12.82, 12.83, and 12.81, respectively. Total accumulated costs over the simulation period were $44,241.09 (chiglitazar 32 mg), $45,044.25 (chiglitazar 48 mg), and $44,821.45 (sitagliptin 100 mg). Long-term economic evaluation revealed that chiglitazar 32 mg provided the optimal cost-effectiveness, whereas sitagliptin 100 mg was the least economically advantageous option. Both one-way and probabilistic sensitivity analyses confirmed the robustness of these findings. Scenario analysis showed that sitagliptin 100 mg only becomes cost-effective when its annual cost is reduced by at least 42.33 % compared to chiglitazar 32 mg.</div></div><div><h3>Conclusion</h3><div>Based on cost-utility analysis within the Chinese healthcare context, chiglitazar demonstrates significantly better long-term health outcomes and cost-effectiveness relative to sitagliptin for T2DM management.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109174"},"PeriodicalIF":3.1,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145047102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of levocetirizine in reducing albuminuria and inflammatory biomarkers in patients with diabetic kidney disease: A randomized controlled trial","authors":"Maryam A. Rizk ,&nbsp;Sahar M. El-Haggar ,&nbsp;Osama M. Ibrahim ,&nbsp;Hossam Arafa Ghazi","doi":"10.1016/j.jdiacomp.2025.109175","DOIUrl":"10.1016/j.jdiacomp.2025.109175","url":null,"abstract":"<div><div>Globally, the prevalence of diabetes mellitus is rising. One of the main causes of end-stage renal disease (ESRD) and a risk factor for higher morbidity and death in diabetic patients is diabetic nephropathy (DN), sometimes referred to as diabetic kidney disease (DKD). DN, a microvascular consequence of diabetes, affects 20–40 % of diabetics globally. The study's objective was to assess if levocetirizine may have albuminuria lowering effect and anti-inflammatory effect in patients treated with angiotensin receptor blockers (ARBs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors therapy by reducing albuminuria and improving DKD indicators.</div></div><div><h3>Patients and methods</h3><div>A controlled, parallel, trial was carried out on sixty DKD patients. Sixty patients were divided into two groups at random. Group 1 (control group) received an empagliflozin 10 mg once day in addition to 80 mg valsartan. Group 2 (levocetirizine group) received the same medications as the control group plus a 5 mg of levocetirizine once daily in the evening, titrated dose based on each patient's creatinine clearance (CrCl) for three months. Serum creatinine, serum urea, serum cystatin-C, HbA₁c, tumor necrosis factor alpha (TNF-α), estimated glomerular filtration rate (eGFR), and urinary albumin to creatinine ratio (UACR) were measured at baseline and compared to these data three months after drug administration.</div></div><div><h3>Results</h3><div>Levocetirizine decreased significantly UACR at the end of the three-months (<em>p</em> = 0.037) compared to the control group. There was no variation in eGFR between the two groups, eGFR was significantly lower than baseline (<em>p</em> &lt; 0.001) in both groups. Comparing the levocetirizine group to the control group, there is a substantial drop in TNF-α (<em>p</em> = 0.004), cystatin-C (<em>p</em> = 0.034), and HbA₁c (<em>p</em> = 0.007).</div></div><div><h3>Conclusion</h3><div>Levocetirizine reduces albuminuria, inflammatory, and renal indicators, which makes it a potentially has albuminuria lowering effect and anti-inflammatory drug which decreases disease progression.</div></div><div><h3>Trial registration identifier</h3><div><span><span>NCT05638880</span><svg><path></path></svg></span></div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109175"},"PeriodicalIF":3.1,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145047103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(25)00220-X","DOIUrl":"10.1016/S1056-8727(25)00220-X","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109167"},"PeriodicalIF":3.1,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145007692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between flow-mediated dilation and urinary albumin-creatinine ratio in patients with type 2 diabetes mellitus","authors":"YuDie Fang ,&nbsp;Lijuan Jing ,&nbsp;YunXia Zhu ,&nbsp;Hongping Wang ,&nbsp;Juan Xia ,&nbsp;Tao Lei ,&nbsp;Jun Lu ,&nbsp;Jie Gao","doi":"10.1016/j.jdiacomp.2025.109162","DOIUrl":"10.1016/j.jdiacomp.2025.109162","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the association between Flow-Mediated Dilation (FMD) and the urinary albumin-to-creatinine ratio (UACR) in individuals with type 2 diabetes mellitus (T2DM).</div></div><div><h3>Methods</h3><div>This cross-sectional study involved 194 individuals diagnosed with T2DM. Participants were categorized into two groups based on their UACR levels: the diabetic kidney disease group (DKD) (UACR≥30 mg/g) and the non-diabetic kidney disease group (non-DKD) (UACR &lt;30 mg/g). The relationship between FMD and UACR was evaluated through Spearman correlation analysis and multivariable logistic regression analysis. Additionally, the predictive capacity of FMD for DKD was determined using receiver operating characteristic curve analysis.</div></div><div><h3>Results</h3><div>Median FMD was lower in DKD group than in non-DKD group (3.9 vs 4.9, <em>p</em> = 0.011). Furthermore, a notable negative correlation was observed between FMD and UACR (<em>r</em> = −0.253, <em>p</em> &lt; 0.05). Through logistic regression analysis, an increase in FMD by one standard deviation (SD) corresponded to a 35.6 % decrease in the likelihood of elevated UACR (OR: 0.644 [0.459–0.904]) (Model 1). Consistent findings were noted even after accounting for variables such as sex, age, BMI, hypertension, smoking habits, and alcohol intake (Model 2), as well as HbA1c levels, disease duration, and triglycerides (Model 3). The area under the ROC curve (AUC) for FMD was 0.686 (95 % CI 0.596–0.777).</div></div><div><h3>Conclusions</h3><div>FMD is independently correlated with UACR, which provides a clinical basis for the prevention and control of vascular complications in early DKD.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109162"},"PeriodicalIF":3.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144925350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in mean serum insulin and hyperinsulinemia among US adults without diabetes 1999–2018","authors":"Tammie M. Johnson ,&nbsp;James R. Churilla","doi":"10.1016/j.jdiacomp.2025.109159","DOIUrl":"10.1016/j.jdiacomp.2025.109159","url":null,"abstract":"<div><h3>Purpose</h3><div>The purpose of this study is to examine trends for mean serum insulin concentration (pmol/L) and prevalence of hyperinsulinemia (≥4.358 pmol/L fasting insulin) in US adults without diabetes.</div></div><div><h3>Methods</h3><div>We used data from the 1999–2018 National Health and Nutrition Examination Survey (NHANES). Participants (<em>n</em> = 14,150) were ≥20 years of age, not pregnant, had no history of diabetes, had a fasting blood glucose measure of less than 126 mg/dL, and had valid responses to all study variables. Consecutive cycles of NHANES data from 1999 to 2018 (20 years) were aggregated into five four-year intervals.</div></div><div><h3>Results</h3><div>The Annual Percent Change (APC) for mean fasting insulin ranged from 5.64 (adjusted for body mass index) to 7.65 % when unadjusted (all <em>p</em>-values for trend &lt;0.0001). The APC for hyperinsulinemia prevalence ranged from 19.4 % (adjusted for waist circumference) to 22.3 % when unadjusted (all <em>p</em>-values for trend &lt;0.0001). The subanalyses by gender consistently revealed significant positive trends for both outcomes.</div></div><div><h3>Conclusions</h3><div>This study illustrates a significant positive trend for mean fasting insulin concentrations and hyperinsulinemia among US adults over 20 years. Monitoring serum insulin and hyperinsulinemia trends provides insights into the continuing rise in type 2 diabetes (T2D) and opportunities for T2D prevention.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109159"},"PeriodicalIF":3.1,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144997677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atypical complications and co-morbidities of type 1 diabetes in young adults","authors":"Steven James ,&nbsp;Rebecca Barber ,&nbsp;Jess Forster ,&nbsp;Lindsay Sawatsky ,&nbsp;Samantha Berry ,&nbsp;Olive James ,&nbsp;Kerrie Abel ,&nbsp;Claire Trigg ,&nbsp;Kim C. Donaghue ,&nbsp;Maria E. Craig ,&nbsp;Mahira Saiyed ,&nbsp;Sheryl S. Salis ,&nbsp;Jamie Wood ,&nbsp;Willem Staels","doi":"10.1016/j.jdiacomp.2025.109158","DOIUrl":"10.1016/j.jdiacomp.2025.109158","url":null,"abstract":"<div><h3>Aims</h3><div>Our review aimed to determine the prevalence of – and factors associated with – hearing loss, oral and olfactory disease, frozen shoulder, trigger finger, and hair loss in young adults with type 1 diabetes. These conditions were selected based on research team interests, existing literature, and group discussion.</div></div><div><h3>Methods</h3><div>We conducted a quantitative narrative review using a systematic process to identify cohort and cross-sectional studies involving young adults with type 1 diabetes (mean age 18–30 years). PubMed, CINAHL, and Cochrane were searched (January 2000–February 2024). Grey literature was not restricted, and quality appraisal was undertaken. Extracted data were synthesised and summarised narratively.</div></div><div><h3>Results</h3><div>The initial search found 3924 records and after title, abstract and full-text review, 19 records met inclusion criteria. Hearing loss prevalence ranged from 22.6 to 48.0 %, with age, diabetes duration, and systolic blood pressure identified as prominent associated features. For oral disease, peridontitis prevalence was 4.7 %, while alveolar bone loss ranged from 24.6 to 43.9 %; age was the primary associated factor. No eligible data were identified regarding frozen shoulder, trigger finger, or hair loss.</div></div><div><h3>Conclusions</h3><div>Further research is needed to characterize the prevalence and risk factors of atypical complications in type 1 diabetes. Clinical care should be guided by a robust understanding of these under-recognised comorbidities.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109158"},"PeriodicalIF":3.1,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145005097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex specific associations of sex hormones with brain volumes and cerebral blood flow: A cross sectional observational study within the look AHEAD type 2 diabetes cohort","authors":"Dhananjay Vaidya ,&nbsp;Yvette Yeboah-Kordieh ,&nbsp;Marjorie Howard ,&nbsp;Christina E. Hugenschmidt ,&nbsp;Paul A. Nyquist ,&nbsp;Erin D. Michos ,&nbsp;Rita R. Kalyani ,&nbsp;Sevil Yasar ,&nbsp;Brian Andres Robusto ,&nbsp;Hussein N. Yassine ,&nbsp;Jeanne M. Clark ,&nbsp;Mark A. Espeland ,&nbsp;Wendy L. Bennett","doi":"10.1016/j.jdiacomp.2025.109161","DOIUrl":"10.1016/j.jdiacomp.2025.109161","url":null,"abstract":"<div><h3>Background</h3><div>Females have greater brain volume and cerebral blood flow than males when controlling for intracranial volume and age. Brain volume decreases after menopause, suggesting a role of sex hormones. We studied the association of sex hormones with brain volume, white matter hyperintensity volumes and cerebral blood flow in people with Type 2 Diabetes and with overweight and obesity conditions that accelerate brain atrophy.</div></div><div><h3>Methods</h3><div>We analyzed data from 215 participants with overweight or obesity and Type 2 Diabetes from the Look AHEAD Brain Magnetic Resonance Imaging ancillary study (mean age 68 years, 73 % postmenopausal female). Estradiol and total testosterone levels were measured with electrochemoluminescence assays. The ratio of brain measurements to intracranial volume was analyzed to account for body size. We analyzed sex hormones as quantitative measures in males, whereas in females we grouped those with detectable vs. undetectable hormone levels (Estradiol &lt;73 pmol/L [20 pg/mL]: 79 %; Total Testosterone &lt;0.07 mmol/L [0.02 ng/mL]: 37 % undetectable in females).</div></div><div><h3>Results</h3><div>Females with detectable total testosterone levels had higher brain volume to intracranial volume ratio (median [25th, 75th percentile]: 0.85 [0.84, 0.86]) as compared to those with undetectable Total Testosterone levels (0.84 [0.83, 0.86]; rank sum <em>p</em> = 0.04). This association was attenuated after age and body mass index adjustment (<em>p</em> = 0.08). Neither white matter hyperintensity volumes or cerebral blood flow in females, nor any brain measures in males, were significantly associated with Estradiol or Total Testosterone.</div></div><div><h3>Conclusions</h3><div>In postmenopausal females with Type 2 Diabetes with overweight and obesity, detectable levels of total testosterone were associated greater brain volume relative to intracranial volume, suggesting a protective role for testosterone in female brain health. Our findings are limited by a small sample size and low sensitivity of hormone assays. Our suggestive findings can be combined with future larger studies to assess clinically important differences.</div></div><div><h3>Trial registration</h3><div><span><span>NCT00017953</span><svg><path></path></svg></span></div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109161"},"PeriodicalIF":3.1,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144917705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Retention and outcomes of National Diabetes Prevention Program enrollees and non-enrollees with prediabetes: The University of Michigan experience\" [J. Diabetes Complicat. (2023) 108527].","authors":"William H Herman, Claudia Villatoro, Kevin L Joiner, Laura N McEwen","doi":"10.1016/j.jdiacomp.2025.109157","DOIUrl":"https://doi.org/10.1016/j.jdiacomp.2025.109157","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":" ","pages":"109157"},"PeriodicalIF":3.1,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the letter to the editor.","authors":"Fernando Sebastian-Valles","doi":"10.1016/j.jdiacomp.2025.109160","DOIUrl":"https://doi.org/10.1016/j.jdiacomp.2025.109160","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":" ","pages":"109160"},"PeriodicalIF":3.1,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}